Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,treasuryStock,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,repurchaseOfStock,WC,language,region,quoteType,triggerable,quoteSourceName,preMarketChange,preMarketChangePercent,preMarketTime,preMarketPrice,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,priceHint,regularMarketChangePercent,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,currency,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchange,shortName,exchangeDataDelayedBy,market,marketState,epsTrailingTwelveMonths,twoHundredDayAverageChangePercent,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 14, 2021) 4","Short Ratio (Jul 14, 2021) 4","Short % of Float (Jul 14, 2021) 4","Short % of Shares Outstanding (Jul 14, 2021) 4","Shares Short (prior month Jun 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,IMV,26598000.0,67795904,,,-6957000,,-6957000,3161000,-4744000,-6671000,-6671000,-1234000,-355000,,,,0,0,6671000,4744000,-286000,,-6957000,-6957000,7953000.0,12794000.0,26598000.0,4606000.0,39392000.0,139714000.0,-125288000.0,4219000.0,30453000.0,5587000.0,868000.0,4219000.0,2229000.0,37163000.0,2217000.0,6271000.0,,-3717000.0,-100000.0,-243000.0,2038000.0,1287000.0,2350000.0,-5815000.0,101000.0,-7854000.0,99000.0,607000.0,-69000.0,827000.0,-100000.0,,31576000.0,en-US,US,EQUITY,True,Delayed Quote,0.00999999,0.5813948,1630573313,1.73,550657,0.4100001,0.31297716,1.31 - 5.06,-3.34,-0.66007906,1.31,5.06,1525910400,1620817140,1620817140,1620817140,0.393,1.6451429,0.074857116,0.04550189,2.4935508,-0.77355075,116608960,4,-2.824856,4.3765903,15,America/New_York,EDT,-14400000,1.69 - 1.82,1.77,0.0,0.0,32,30,finmb_7828330,NasdaqCM,IMV Inc.,USD,3243360,USD,False,False,1.72,1630526403,-0.049999952,1.81,1.82,1.69,640224,NCM,IMV Inc.,0,us_market,PRE,-0.426,-0.31022057,1.85,,,5.06,1.31,1.6451,2.4936,3.24M,550.66k,67.8M,,61.84M,0.74%,24.09%,589.7k,1.73,,0.87%,662.97k,,,,,,0.00%,"May 09, 2018",,312:1000,"May 09, 2018","Dec 30, 2020","Mar 30, 2021",0.00%,"-1,326,742.77%",-78.78%,-220.73%,2.38k,0.00,,-26.6M,-31.36M,-27.47M,-0.4260,,30.45M,0.45,8.19M,30.78,6.65,0.39,-30.17M,-22.22M,Value,B3B 2C4,Healthcare,77,3,4,"IMV Inc., a biopharmaceutical company, focuses on the development of cancer immunotherapies and vaccines against infectious diseases using its DPX delivery technology platform. The company's lead drug candidate includes maveropepimut-S (DPX-Survivac), a T cell therapy, which is in three Phase II clinical trials across 6 different cancer indications with and without Merck's Keytruda; and Phase II clinical trials for the treatment of ovarian cancer, and recurrent and refractory diffuse large B cell lymphoma. It is also developing DPX-COVID-19, a second-generation vaccine against severe acute respiratory syndrome coronavirus 2; and DPX-RSV, a vaccine candidate, which has completed Phase I clinical trials for the treatment of respiratory syncytial virus strain A, as well as DPX-SurMAGE for the treatment of bladder cancer and DPX-BRAF to treat melanoma patients. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.",Dartmouth,902 492 1819,NS,6,1609372800,1625097600,8,Canada,http://www.imv-inc.com,86400,6,130 Eileen Stubbs Avenue,902 492 0888,Biotechnology,Suite 19
t-1,IMV,39375000.0,67795904,,,-9596000,,-9596000,5427000,-7977000,-15363000,-15363000,1959000,-355000,,,,0,0,15363000,7977000,5767000,,-9596000,-9596000,9972000.0,19425000.0,39375000.0,58000.0,58800000.0,181355000.0,-154974000.0,3022000.0,46362000.0,10473000.0,1094000.0,3022000.0,2839000.0,55961000.0,3954000.0,7734000.0,4757000.0,2820000.0,-188000.0,-558000.0,-813000.0,843000.0,2350000.0,-8338000.0,101000.0,-7337000.0,134000.0,-1249000.0,3520000.0,-289000.0,-188000.0,-3775000.0,45488000.0,en-US,US,EQUITY,True,Delayed Quote,0.00999999,0.5813948,1630573313,1.73,550657,0.4100001,0.31297716,1.31 - 5.06,-3.34,-0.66007906,1.31,5.06,1525910400,1620817140,1620817140,1620817140,0.393,1.6451429,0.074857116,0.04550189,2.4935508,-0.77355075,116608960,4,-2.824856,4.3765903,15,America/New_York,EDT,-14400000,1.69 - 1.82,1.77,0.0,0.0,32,30,finmb_7828330,NasdaqCM,IMV Inc.,USD,3243360,USD,False,False,1.72,1630526403,-0.049999952,1.81,1.82,1.69,640224,NCM,IMV Inc.,0,us_market,PRE,-0.426,-0.31022057,1.85,,,5.06,1.31,1.6451,2.4936,3.24M,550.66k,67.8M,,61.84M,0.74%,24.09%,589.7k,1.73,,0.87%,662.97k,,,,,,0.00%,"May 09, 2018",,312:1000,"May 09, 2018","Dec 30, 2020","Mar 30, 2021",0.00%,"-1,326,742.77%",-78.78%,-220.73%,2.38k,0.00,,-26.6M,-31.36M,-27.47M,-0.4260,,30.45M,0.45,8.19M,30.78,6.65,0.39,-30.17M,-22.22M,Value,B3B 2C4,Healthcare,77,3,4,"IMV Inc., a biopharmaceutical company, focuses on the development of cancer immunotherapies and vaccines against infectious diseases using its DPX delivery technology platform. The company's lead drug candidate includes maveropepimut-S (DPX-Survivac), a T cell therapy, which is in three Phase II clinical trials across 6 different cancer indications with and without Merck's Keytruda; and Phase II clinical trials for the treatment of ovarian cancer, and recurrent and refractory diffuse large B cell lymphoma. It is also developing DPX-COVID-19, a second-generation vaccine against severe acute respiratory syndrome coronavirus 2; and DPX-RSV, a vaccine candidate, which has completed Phase I clinical trials for the treatment of respiratory syncytial virus strain A, as well as DPX-SurMAGE for the treatment of bladder cancer and DPX-BRAF to treat melanoma patients. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.",Dartmouth,902 492 1819,NS,6,1609372800,1625097600,8,Canada,http://www.imv-inc.com,86400,6,130 Eileen Stubbs Avenue,902 492 0888,Biotechnology,Suite 19
t-2,IMV,48804000.0,67795904,,,-8327000,,-8327000,3699000,-6538000,-8553000,-8553000,-1684000,-355000,,,,0,3000,8556000,6541000,226000,,-8327000,-8327000,9550000.0,19171000.0,48804000.0,62000.0,67975000.0,181610000.0,-145378000.0,3022000.0,54700000.0,9267000.0,843000.0,3022000.0,2833000.0,65142000.0,3251000.0,8670000.0,8236000.0,-540000.0,-164000.0,-1185000.0,33200000.0,2224000.0,35461000.0,26449000.0,101000.0,-6587000.0,136000.0,248000.0,-1076000.0,-332000.0,-164000.0,-3775000.0,55875000.0,en-US,US,EQUITY,True,Delayed Quote,0.00999999,0.5813948,1630573313,1.73,550657,0.4100001,0.31297716,1.31 - 5.06,-3.34,-0.66007906,1.31,5.06,1525910400,1620817140,1620817140,1620817140,0.393,1.6451429,0.074857116,0.04550189,2.4935508,-0.77355075,116608960,4,-2.824856,4.3765903,15,America/New_York,EDT,-14400000,1.69 - 1.82,1.77,0.0,0.0,32,30,finmb_7828330,NasdaqCM,IMV Inc.,USD,3243360,USD,False,False,1.72,1630526403,-0.049999952,1.81,1.82,1.69,640224,NCM,IMV Inc.,0,us_market,PRE,-0.426,-0.31022057,1.85,,,5.06,1.31,1.6451,2.4936,3.24M,550.66k,67.8M,,61.84M,0.74%,24.09%,589.7k,1.73,,0.87%,662.97k,,,,,,0.00%,"May 09, 2018",,312:1000,"May 09, 2018","Dec 30, 2020","Mar 30, 2021",0.00%,"-1,326,742.77%",-78.78%,-220.73%,2.38k,0.00,,-26.6M,-31.36M,-27.47M,-0.4260,,30.45M,0.45,8.19M,30.78,6.65,0.39,-30.17M,-22.22M,Value,B3B 2C4,Healthcare,77,3,4,"IMV Inc., a biopharmaceutical company, focuses on the development of cancer immunotherapies and vaccines against infectious diseases using its DPX delivery technology platform. The company's lead drug candidate includes maveropepimut-S (DPX-Survivac), a T cell therapy, which is in three Phase II clinical trials across 6 different cancer indications with and without Merck's Keytruda; and Phase II clinical trials for the treatment of ovarian cancer, and recurrent and refractory diffuse large B cell lymphoma. It is also developing DPX-COVID-19, a second-generation vaccine against severe acute respiratory syndrome coronavirus 2; and DPX-RSV, a vaccine candidate, which has completed Phase I clinical trials for the treatment of respiratory syncytial virus strain A, as well as DPX-SurMAGE for the treatment of bladder cancer and DPX-BRAF to treat melanoma patients. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.",Dartmouth,902 492 1819,NS,6,1609372800,1625097600,8,Canada,http://www.imv-inc.com,86400,6,130 Eileen Stubbs Avenue,902 492 0888,Biotechnology,Suite 19
t-3,IMV,22335000.0,67795904,,,-7268000,,-7268000,3047000,-5260000,-6901000,-6901000,-1406000,-422000,,,,0,0,6901000,5260000,-367000,,-7268000,-7268000,9152000.0,19067000.0,22335000.0,75000.0,41402000.0,146463000.0,-137055000.0,3775000.0,28251000.0,9076000.0,592000.0,3775000.0,2825000.0,38577000.0,2353000.0,8696000.0,8286000.0,-1925000.0,-57000.0,3064000.0,34806000.0,-5286000.0,32171000.0,20879000.0,101000.0,-13870000.0,124000.0,-258000.0,-429000.0,747000.0,-57000.0,-3775000.0,29501000.0,en-US,US,EQUITY,True,Delayed Quote,0.00999999,0.5813948,1630573313,1.73,550657,0.4100001,0.31297716,1.31 - 5.06,-3.34,-0.66007906,1.31,5.06,1525910400,1620817140,1620817140,1620817140,0.393,1.6451429,0.074857116,0.04550189,2.4935508,-0.77355075,116608960,4,-2.824856,4.3765903,15,America/New_York,EDT,-14400000,1.69 - 1.82,1.77,0.0,0.0,32,30,finmb_7828330,NasdaqCM,IMV Inc.,USD,3243360,USD,False,False,1.72,1630526403,-0.049999952,1.81,1.82,1.69,640224,NCM,IMV Inc.,0,us_market,PRE,-0.426,-0.31022057,1.85,,,5.06,1.31,1.6451,2.4936,3.24M,550.66k,67.8M,,61.84M,0.74%,24.09%,589.7k,1.73,,0.87%,662.97k,,,,,,0.00%,"May 09, 2018",,312:1000,"May 09, 2018","Dec 30, 2020","Mar 30, 2021",0.00%,"-1,326,742.77%",-78.78%,-220.73%,2.38k,0.00,,-26.6M,-31.36M,-27.47M,-0.4260,,30.45M,0.45,8.19M,30.78,6.65,0.39,-30.17M,-22.22M,Value,B3B 2C4,Healthcare,77,3,4,"IMV Inc., a biopharmaceutical company, focuses on the development of cancer immunotherapies and vaccines against infectious diseases using its DPX delivery technology platform. The company's lead drug candidate includes maveropepimut-S (DPX-Survivac), a T cell therapy, which is in three Phase II clinical trials across 6 different cancer indications with and without Merck's Keytruda; and Phase II clinical trials for the treatment of ovarian cancer, and recurrent and refractory diffuse large B cell lymphoma. It is also developing DPX-COVID-19, a second-generation vaccine against severe acute respiratory syndrome coronavirus 2; and DPX-RSV, a vaccine candidate, which has completed Phase I clinical trials for the treatment of respiratory syncytial virus strain A, as well as DPX-SurMAGE for the treatment of bladder cancer and DPX-BRAF to treat melanoma patients. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.",Dartmouth,902 492 1819,NS,6,1609372800,1625097600,8,Canada,http://www.imv-inc.com,86400,6,130 Eileen Stubbs Avenue,902 492 0888,Biotechnology,Suite 19
